Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. Clinical Characteristics
3.2. Chromsomal Translocation
3.3. Somatic Mutations Detected in H. pylori Negative MALT Lymphoma
3.4. Response to Treatment and Long-Term Outcome
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Teras, L.R.; DeSantis, C.E.; Cerhan, J.R.; Morton, L.M.; Jemal, A.; Flowers, C.R. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 2016, 66, 443–459. [Google Scholar] [CrossRef]
- Cook, J.R.; Chott, A.; Nakamura, S.; Müller-Hermelink, H.K.; Harris, N.L.; Swerdlow, S.H. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.; Swerdlow, S.H., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Eds.; IARC: Lyon, France, 2017; pp. 259–262. [Google Scholar]
- Troppan, K.; Wenzl, K.; Neumeister, P.; Deutsch, A. Molecular Pathogenesis of MALT Lymphoma. Gastroenterol. Res. Pract. 2015, 2015, 102656. [Google Scholar] [CrossRef] [Green Version]
- Raderer, M.; Kiesewetter, B.; Ferreri, A.J.M. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J. Clin. 2016, 66, 152–171. [Google Scholar] [CrossRef] [PubMed]
- Wotherspoon, A.C.; Ortiz-Hidalgo, C.; Falzon, M.R.; Isaacson, P.G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991, 338, 1175–1176. [Google Scholar] [CrossRef]
- Sagaert, X.; Van Cutsem, E.; De Hertogh, G.; Geboes, K.; Tousseyn, T. Gastric MALT lymphoma: A model of chronic inflammation-induced tumor development. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 336–346. [Google Scholar] [CrossRef]
- Wündisch, T.; Thiede, C.; Morgner, A.; Dempfle, A.; Günther, A.; Liu, H.; Ye, H.; Du, M.-Q.; Kim, T.D.; Bayerdörffer, E.; et al. Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori Eradication. J. Clin. Oncol. 2005, 23, 8018–8024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruskoné-Fourmestraux, A.; Fischbach, W.; Aleman, B.M.; Boot, H.; Du, M.Q.; Megraud, F.; Montalban, C.; Raderer, M.; Savio, A.; Wotherspoon, A. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011, 60, 747–758. [Google Scholar] [CrossRef] [Green Version]
- Zucca, E.; Arcaini, L.; Buske, C.; Johnson, P.W.; Ponzoni, M.; Raderer, M.; Ricardi, U.; Salar, A.; Stamatopoulos, K.; Thieblemont, C.; et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020, 31, 17–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakamura, S.; Sugiyama, T.; Matsumoto, T.; Iijima, K.; Ono, S.; Tajika, M.; Tari, A.; Kitadai, Y.; Matsumoto, H.; Nagaya, T.; et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: A multicentre cohort follow-up study of 420 patients in Japan. Gut 2012, 61, 507. [Google Scholar] [CrossRef]
- Asano, N.; Iijima, K.; Koike, T.; Imatani, A.; Shimosegawa, T. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review. World J. Gastroenterol. 2015, 21, 8014–8020. [Google Scholar] [CrossRef] [PubMed]
- Kiesewetter, B.; Simonitsch-Klupp, I.; Dolak, W.; Mayerhoefer, M.E.; Raderer, M. Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Cancers 2020, 12, 492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakamura, S.; Matsumoto, T.; Ye, H.; Nakamura, S.; Suekane, H.; Matsumoto, H.; Yao, T.; Tsuneyoshi, M.; Du, M.Q.; Iida, M. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A clinicopathologic and molecular study with reference to antibiotic treatment. Cancer 2006, 107, 2770–2778. [Google Scholar] [CrossRef]
- Du, M.Q. MALT lymphoma: A paradigm of NF-κB dysregulation. Semin. Cancer Biol. 2016, 39, 49–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cascione, L.; Rinaldi, A.; Bruscaggin, A.; Tarantelli, C.; Arribas, A.J.; Kwee, I.; Pecciarini, L.; Mensah, A.A.; Spina, V.; Chung, E.Y.L.; et al. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica 2019, 104, e558–e561. [Google Scholar] [CrossRef] [PubMed]
- Moody, S.; Thompson, J.S.; Chuang, S.S.; Liu, H.; Raderer, M.; Vassiliou, G.; Wlodarska, I.; Wu, F.; Cogliatti, S.; Robson, A.; et al. Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites. Haematologica 2018, 103, 1329–1336. [Google Scholar] [CrossRef] [Green Version]
- Hyeon, J.; Lee, B.; Shin, S.-H.; Yoo, H.Y.; Kim, S.J.; Kim, W.S.; Park, W.-Y.; Ko, Y.-H. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Mod. Pathol. 2018, 31, 1418–1428. [Google Scholar] [CrossRef]
- Ye, H.; Liu, H.; Raderer, M.; Chott, A.; Ruskone-Fourmestraux, A.; Wotherspoon, A.; Dyer, M.J.; Chuang, S.S.; Dogan, A.; Isaacson, P.G.; et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003, 101, 2547–2550. [Google Scholar] [CrossRef]
- Thieblemont, C.; Cascione, L.; Conconi, A.; Kiesewetter, B.; Raderer, M.; Gaidano, G.; Martelli, M.; Laszlo, D.; Coiffier, B.; Lopez Guillermo, A.; et al. A MALT lymphoma prognostic index. Blood 2017, 130, 1409–1417. [Google Scholar] [CrossRef] [Green Version]
- Copie-Bergman, C.; Wotherspoon, A.C.; Capella, C.; Motta, T.; Pedrinis, E.; Pileri, S.A.; Bertoni, F.; Conconi, A.; Zucca, E.; Ponzoni, M.; et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br. J. Haematol. 2013, 160, 47–52. [Google Scholar] [CrossRef] [PubMed]
- Cucco, F.; Clipson, A.; Kennedy, H.; Sneath Thompson, J.; Wang, M.; Barrans, S.; van Hoppe, M.; Ochoa Ruiz, E.; Caddy, J.; Hamid, D.; et al. Mutation screening using formalin-fixed paraffin-embedded tissues: A stratified approach according to DNA quality. Lab. Investig. 2018, 98, 1084–1092. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, F.; Watanabe, N.; Tzioni, M.; Akarca, A.; Zhang, C.; Li, Y.; Chen, Z.; Cucco, F.; Carmell, N.; Noh, J.Y.; et al. Thyroid MALT lymphoma: Self-harm to gain potential T-cell help. Leukemia 2021, in press. [Google Scholar] [CrossRef]
- Ye, H.; Liu, H.; Attygalle, A.; Wotherspoon, A.C.; Nicholson, A.G.; Charlotte, F.; Leblond, V.; Speight, P.; Goodlad, J.; Lavergne-Slove, A.; et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: Significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003, 102, 1012–1018. [Google Scholar] [CrossRef] [PubMed]
- Rosebeck, S.; Madden, L.; Jin, X.; Gu, S.; Apel, I.J.; Appert, A.; Hamoudi, R.A.; Noels, H.; Sagaert, X.; Van Loo, P.; et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011, 331, 468–472. [Google Scholar] [CrossRef] [Green Version]
- Wöhrer, S.; Troch, M.; Streubel, B.; Zwerina, J.; Skrabs, C.; Formanek, M.; Hauff, W.; Hoffmann, M.; Müllauer, L.; Chott, A.; et al. MALT lymphoma in patients with autoimmune diseases: A comparative analysis of characteristics and clinical course. Leukemia 2007, 21, 1812–1818. [Google Scholar] [CrossRef] [Green Version]
- Teckie, S.; Qi, S.; Lovie, S.; Navarrett, S.; Hsu, M.; Noy, A.; Portlock, C.; Yahalom, J. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int. J. Radiat. Oncol. Biol. Phys. 2015, 92, 130–137. [Google Scholar] [CrossRef]
- Amiot, A.; Lévy, M.; Copie-Bergman, C.; Dupuis, J.; Szablewski, V.; Le Baleur, Y.; Baia, M.; Belhadj, K.; Sobhani, I.; Leroy, K.; et al. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: A monocentric non-randomised observational study. Aliment. Pharm. 2014, 39, 619–628. [Google Scholar] [CrossRef]
- Lévy, M.; Copie-Bergman, C.; Gameiro, C.; Chaumette, M.-T.; Delfau-Larue, M.-H.; Haioun, C.; Charachon, A.; Hemery, F.; Gaulard, P.; Leroy, K.; et al. Prognostic Value of Translocation t(11;18) in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral Chemotherapy. J. Clin. Oncol. 2005, 23, 5061–5066. [Google Scholar] [CrossRef]
- Jung, K.; Kim, D.H.; Seo, H.I.; Gong, E.J.; Bang, C.S. Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis. Helicobacter 2021, 26, e12774. [Google Scholar] [CrossRef] [PubMed]
- Raderer, M.; Streubel, B.; Wöhrer, S.; Häfner, M.; Chott, A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006, 55, 616–618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zullo, A.; Hassan, C.; Ridola, L.; De Francesco, V.; Rossi, L.; Tomao, S.; Vaira, D.; Genta, R.M. Eradication Therapy in Helicobacter pylori-negative, Gastric Low-grade Mucosa–associated Lymphoid Tissue Lymphoma Patients: A Systematic Review. J. Clin. Gastroenterol. 2013, 47, 824–827. [Google Scholar] [CrossRef]
- Kiesewetter, B.; Raderer, M. Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Hematol. Oncol. 2020, 38, 417–424. [Google Scholar] [CrossRef]
- Ferreri, A.J.M.; Cecchetti, C.; Kiesewetter, B.; Sassone, M.; Calimeri, T.; Perrone, S.; Ponzoni, M.; Raderer, M. Clarithromycin as a “repurposing drug” against MALT lymphoma. Br. J. Haematol. 2018, 182, 913–915. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raderer, M.; Wöhrer, S.; Kiesewetter, B.; Dolak, W.; Lagler, H.; Wotherspoon, A.; Muellauer, L.; Chott, A. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: A single center experience with prolonged follow-up. Ann. Hematol. 2015, 94, 969–973. [Google Scholar] [CrossRef]
- Kuo, S.H.; Yeh, K.H.; Wu, M.S.; Lin, C.W.; Wei, M.F.; Liou, J.M.; Wang, H.P.; Chen, L.T.; Cheng, A.L. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Sci. Rep. 2017, 7, 14333. [Google Scholar] [CrossRef] [Green Version]
- Nakamura, M.; Øverby, A.; Michimae, H.; Matsui, H.; Takahashi, S.; Mabe, K.; Shimoyama, T.; Sasaki, M.; Terao, S.; Kamada, T.; et al. PCR analysis and specific immunohistochemistry revealing a high prevalence of non-Helicobacter pylori Helicobacters in Helicobacter pylori-negative gastric disease patients in Japan: High susceptibility to an Hp eradication regimen. Helicobacter 2020, 25, e12700. [Google Scholar] [CrossRef] [PubMed]
- Takigawa, H.; Yuge, R.; Masaki, S.; Otani, R.; Kadota, H.; Naito, T.; Hayashi, R.; Urabe, Y.; Oka, S.; Tanaka, S.; et al. Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy. Gastric Cancer 2021. [Google Scholar] [CrossRef]
- Fontán, L.; Melnick, A. Molecular pathways: Targeting MALT1 paracaspase activity in lymphoma. Clin. Cancer Res. 2013, 19, 6662–6668. [Google Scholar] [CrossRef] [Green Version]
- Fontan, L.; Yang, C.; Kabaleeswaran, V.; Volpon, L.; Osborne, M.J.; Beltran, E.; Garcia, M.; Cerchietti, L.; Shaknovich, R.; Yang, S.N.; et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012, 22, 812–824. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pissot Soldermann, C.; Simic, O.; Renatus, M.; Erbel, P.; Melkko, S.; Wartmann, M.; Bigaud, M.; Weiss, A.; McSheehy, P.; Endres, R.; et al. Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing. J. Med. Chem. 2020, 63, 14576–14593. [Google Scholar] [CrossRef]
- Stephenson, R.; Singh, A. Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. Adv. Drug Deliv. Rev. 2017, 114, 285–300. [Google Scholar] [CrossRef] [PubMed]
- Conconi, A.; Martinelli, G.; Lopez-Guillermo, A.; Zinzani, P.L.; Ferreri, A.J.M.; Rigacci, L.; Devizzi, L.; Vitolo, U.; Luminari, S.; Cavalli, F.; et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann. Oncol. 2011, 22, 689–695. [Google Scholar] [CrossRef] [PubMed]
- Troch, M.; Jonak, C.; Müllauer, L.; Püspök, A.; Formanek, M.; Hauff, W.; Zielinski, C.C.; Chott, A.; Raderer, M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009, 94, 738–742. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Clinical Characteristics | Entire Collective (n = 57) | NGS Collective (n = 35/57) |
---|---|---|
Sex (female/ male) | 52.6% (30/57)/47.4% (27/57) | 51.4% (18/35)/48.6% (17/35) |
Age (median) | 61.8 years (range 36–84) | 65.7 years (range 36–80) |
H. pylori negativity confirmed by | ||
Histology | 100% (57/57) | 100% (35/35) |
PCR for H. pylori | 56.1% (32/57) | 48.6% (17/35) |
Serology | 35.1% (20/57) | 42.9% (15/35) |
Breath test | 7% (4/57) | 2.9% (1/35) |
Stool antigen test | 3.5% (2/57) | - |
Lugano staging system | ||
Lugano stage I | 59.6% (34/57) | 62.9% (22/35) |
Lugano stage II | 17.5% (10/57) | 20% (7/35) |
Lugano stage IV | 22.8% (13/57) | 17.1% (6/35) |
MALT IPI status | ||
Low risk | 47.4% (27/57) | 51.4% (18/35) |
Intermediate risk | 47.4% (27/57) | 45.7% (16/35) |
High risk | 5.3% (3/57 | 2.9% (1/57) |
Further clinical features | ||
Autoimmune disorder | 3.5% (2/57) | 5.7% (2/35) |
LDH > upper normal limit | 5.3% (3/57) | 5.7% (2/35) |
Hepatitis B/C virus | 3.5% (2/57) | none |
Translocation status | ||
MALT1 rearrangement | 38.6% (22/57) | 31.4% (11/35) |
IGH rearrangement | 23.5% (12/51) | 28.1% (9/32) |
First line treatment | ||
Chemo-/immunotherapy | 77.2% (44/57) | 71.4% (25/35) |
Antibiotics (=eradication) | 15.8% (9/57) | 22.9% (8/35) |
Watch and wait | 3.5% (2/57) | 5.7% (2/35) |
Radiotherapy | 1.8% (1/57) | - |
Antiviral therapy hepatitis | 1.8% (1/57 | - |
Median follow-up time (IQR) | 78.4 months (44.9–112) | 66.5 months (23.9–98.3) |
Treatment/Response | Outcome |
---|---|
Entire Collective (n = 57) | |
Complete remission | 28.1% (16/57) |
Partial remission | 43.9% (25/57) |
Stable disease | 28.1% (16/57) |
PFS (median) months | 66.3 (95%CI 5.4–127.2) |
Actively treated collective * (n = 55) | |
Complete remission | 29.1% (16/55) |
Partial remission | 45.5% (25/55) |
Stable disease | 25.5% (14/55) |
PFS (median) months | 66.3 (95%CI 5.4–127.2) |
Chemo-/immunotherapy (n = 44) ** | |
Complete remission | 31.8% (14/44) |
Partial remission | 52.3% (23/44) |
Stable disease | 15.9% (7/44) |
PFS (median) months | 82.7 (95%CI 26.5–138.9) |
Antibiotics (HP eradication) (n = 9) | |
Complete remission | None |
Partial remission | 22.2% (2/9) |
Stable disease | 77.8% (7/9) |
PFS (median) months | 19.2 (95%CI 6.9–31.5) |
Watch and wait (n = 2) | |
Stable disease | 100% (2/2) |
PFS (absolute) months | 5.1 and 0.9 |
Radiotherapy (n = 1) | |
Complete remission | 100% (1/1) |
PFS (absolute) months | 84.0 |
Antiviral therapy hepatitis (n = 1) | |
Complete remission | 100% (1/1) |
PFS (absolute) months | 105.2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kiesewetter, B.; Copie-Bergman, C.; Levy, M.; Wu, F.; Dupuis, J.; Barau, C.; Arcaini, L.; Paulli, M.; Lucioni, M.; Bonometti, A.; et al. Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers 2021, 13, 2993. https://doi.org/10.3390/cancers13122993
Kiesewetter B, Copie-Bergman C, Levy M, Wu F, Dupuis J, Barau C, Arcaini L, Paulli M, Lucioni M, Bonometti A, et al. Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers. 2021; 13(12):2993. https://doi.org/10.3390/cancers13122993
Chicago/Turabian StyleKiesewetter, Barbara, Christiane Copie-Bergman, Michael Levy, Fangtian Wu, Jehan Dupuis, Caroline Barau, Luca Arcaini, Marco Paulli, Marco Lucioni, Arturo Bonometti, and et al. 2021. "Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma" Cancers 13, no. 12: 2993. https://doi.org/10.3390/cancers13122993